Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates

被引:147
|
作者
Zhao, Robert Y. [1 ]
Wilhelm, Sharon D. [1 ]
Audette, Charlene [1 ]
Jones, Gregory [1 ]
Leece, Barbara A. [1 ]
Lazar, Alexandru C. [1 ]
Goldmacher, Victor S. [1 ]
Singh, Rajeeva [1 ]
Kovtun, Yelena [1 ]
Widdison, Wayne C. [1 ]
Lambert, John M. [1 ]
Chari, Ravi V. J. [1 ]
机构
[1] ImmunoGen Inc, Waltham, MA 02451 USA
关键词
CALICHEAMICIN CONJUGATE; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; CANCER; CELLS; DOXORUBICIN; ACID; TRANSPORTERS; CHEMOTHERAPY; SPECIFICITY;
D O I
10.1021/jm2002958
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis and biological evaluation of hydrophilic heterobifunctional cross-linkers for conjugation of antibodies with highly cytotoxic agents are described. These linkers contain either a negatively charged sulfonate group or a hydrophilic, noncharged PEG group in addition to an amine-reactive N-hydroxysuccinimide (NHS) ester and sulfhydryl reactive termini. These hydrophilic linkers enable conjugation of hydrophobic organic molecule drugs, such as a maytansinoid, at a higher drug/antibody ratio (DAR) than hydrophobic SPDB and SMCC linkers used earlier without triggering aggregation or loss of affinity of the resulting conjugate. Antibody maytansinoid conjugates (AMCs) bearing these sulfonate- or PEG-containing hydrophilic linkers were, depending on the nature of the targeted cells, equally to more cytotoxic to antigen-positive cells and equally to less cytotoxic to antigen-negative cells than conjugates made with SPDB or SMCC linkers and thus typically displayed a wider selectivity window, particularly against multidrug resistant (MDR) cancer cell lines in vitro and tumor xenograft models in vivo.
引用
收藏
页码:3606 / 3623
页数:18
相关论文
共 50 条
  • [21] Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates
    Erickson, Hans K.
    Widdison, Wayne C.
    Mayo, Michele F.
    Whiteman, Kathleen
    Audette, Charlene
    Wilhelm, Sharon D.
    Singh, Rajeeva
    BIOCONJUGATE CHEMISTRY, 2010, 21 (01) : 84 - 92
  • [22] ADME of Antibody–Maytansinoid Conjugates
    Hans K. Erickson
    John M. Lambert
    The AAPS Journal, 2012, 14 : 799 - 805
  • [23] Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing
    Erickson, HK
    Park, PU
    Widdison, WC
    Kovtun, YV
    Garrett, LM
    Hoffman, K
    Lutz, RJ
    Goldmacher, VS
    Blättler, WA
    CANCER RESEARCH, 2006, 66 (08) : 4426 - 4433
  • [24] Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
    Liang Feng
    Hang-Ping Yao
    Sharad Sharma
    Yong-Qing Zhou
    Jianwei Zhou
    Ruiwen Zhang
    Ming-Hai Wang
    Journal of Experimental & Clinical Cancer Research, 35
  • [25] Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
    Feng, Liang
    Yao, Hang-Ping
    Zhou, Yong-Qing
    Zhou, Jianwei
    Zhang, Ruiwen
    Wang, Ming-Hai
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35
  • [26] Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates
    Ponte, Jose F.
    Sun, Xiuxia
    Yoder, Nicholas C.
    Fishkin, Nathan
    Laleau, Rassol
    Coccia, Jennifer
    Lanieri, Leanne
    Bogalhas, Megan
    Wang, Lintao
    Wilhelm, Sharon
    Widdison, Wayne
    Pinkas, Jan
    Keating, Thomas A.
    Chari, Ravi
    Erickson, Hans K.
    Lambert, John M.
    BIOCONJUGATE CHEMISTRY, 2016, 27 (07) : 1588 - 1598
  • [27] Erratum to: Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer
    Liang Feng
    Hang-Ping Yao
    Sharad Sharma
    Yong-Qing Zhou
    Jianwei Zhou
    Ruiwen Zhang
    Ming-Hai Wang
    Journal of Experimental & Clinical Cancer Research, 35
  • [28] Disulfide-Linked Antibody-Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage
    Kellogg, Brenda A.
    Garrett, Lisa
    Kovtun, Yelena
    Lai, Katharine C.
    Leece, Barbara
    Miller, Michael
    Payne, Gillian
    Steeves, Rita
    Whiteman, Kathleen R.
    Widdison, Wayne
    Xie, Hongsheng
    Singh, Rajeeva
    Chari, Ravi V. J.
    Lambert, John M.
    Lutz, Robert J.
    BIOCONJUGATE CHEMISTRY, 2011, 22 (04) : 717 - 727
  • [29] Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates
    Walker, Joshua A.
    Sorkin, Michelle R.
    Ledesma, Francis
    Kabaria, Sneha R.
    Barfield, Robyn M.
    Rabuka, David
    Alabi, Christopher A.
    BIOCONJUGATE CHEMISTRY, 2019, 30 (11) : 2982 - 2988
  • [30] The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
    Frigerio, Mark
    Kyle, Andrew F.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2017, 17 (32) : 3393 - 3424